OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ghobadi Discusses the Logistics of CAR T-Cell Therapy

January 23rd 2019

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the logistics of chimeric antigen receptor (CAR) T-cell therapy.

Dr. Phillips Discusses Novel Treatment Regimen in MCL

January 23rd 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses a novel treatment regimen for patients with mantle cell lymphoma.

Dr. Choueiri Discusses Immunotherapy in RCC

January 23rd 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Markman Discusses Concept of Precision Medicine in Gynecologic Cancers

January 23rd 2019

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the concept of precision medicine in gynecologic cancers.

Dr. Geyer on Impact of Targeted Agents in HER2+ Breast Cancer

January 22nd 2019

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. Seymour Discusses Rationale for MURANO Study in CLL

January 22nd 2019

John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the rationale for the MURANO study in patients with chronic lymphocytic leukemia.

Dr. Ribas on Combination Immunotherapy and Radiation in Melanoma

January 22nd 2019

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.

Dr. George on the Phase III TAGS Trial in Gastric/GEJ Cancer

January 22nd 2019

Ben George, MD, assistant professor, Medical College of Wisconsin, discusses the phase III TAGS trial in patients with gastric or gastroesophageal junction (GEJ) cancer.

Dr. Jagannath on Treatment Advances in Transplant-Ineligible Patients With Myeloma

January 22nd 2019

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma.

Dr. Davar on the Rationale for the Combination of Anti-TIM-3 and Anti-PD-1

January 22nd 2019

Diwakar Davar, MD, assistant professor of medicine, Department of Medicine, Hematology/Oncology, University of Pittsburgh, discusses the rationale for the combination of anti-TIM-3 and anti-PD-1 in multiple tumor types.

Dr. Abou-Alfa on the FDA Approval of Cabozantinib in HCC

January 20th 2019

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the FDA approval of cabozantinib (Cabometyx) is likely to shake up the landscape and impact sequencing for patients with hepatocellular carcinoma (HCC).

Dr. Chari on Treatment of Penta-Refractory Patients With Myeloma

January 19th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Dr. Pegram Discusses Challenges Once Biosimilars Hit US Market

January 19th 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses challenges biosimilars will face once they hit the United States market.

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast Cancer

January 19th 2019

Mothaffar F. Rimawi, MD, an associate professor and director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the KATHERINE trial in HER2-positive breast cancer.

Dr. Grivas on Promising Combination Therapies in Bladder Cancer

January 19th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.

Extending the Promise of Immunotherapy to Pancreatic Cancer

January 19th 2019

Stephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.

Dr. Dean on Challenges in the MCL Paradigm

January 19th 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.

Dr. Narang Discusses Role of Radiation in Pancreatic Cancer

January 18th 2019

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses the role of radiation therapy in the treatment of patients with pancreatic cancer.

Dr. Sabari Discusses Role of Immunotherapy in SCLC

January 18th 2019

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses the role of immunotherapy in the treatment of patients with small cell lung cancer.

Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCC

January 18th 2019

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.